David A. Luckenbaugh

23.9k citations

159 papers · 17.9k indexed · 3 hit papers · h-index 72

Impact in

Biological Psychiatry top 0.01%
- Tryptophan and brain disorders
Behavioral Neuroscience top 0.1%
- Stress Responses and Cortisol

Papers in

Biological Psychiatry 47
- Tryptophan and brain disorders 47
Behavioral Neuroscience 20
- Stress Responses and Cortisol 20

Co-authors: Carlos A. Zarate Nancy E. Brutsché Dennis S. Charney Husseini K. Manji Rezvan Ameli Jaskaran Singh Paul J. Carlson Robert M. Post
Journals: Biological Psychiatry (22 papers)The Journal of Clinical Psychiatry (15 papers)Journal of Affective Disorders (15 papers)American Journal of Psychiatry (11 papers)Bipolar Disorders (9 papers)
Partner nations: United States Czechia Netherlands

In The Last Decade

David A. Luckenbaugh

159 papers receiving 17.4k citations

Hit Papers

align trajectories log scale

Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial 2012 · 607 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2012 Biological Psychiatry
2010 Archives of General Psychiatry
2006 Archives of General Psychiatry

Peers

Countries citing papers authored by David A. Luckenbaugh

Since Specialization

Citations

This map shows the geographic impact of David A. Luckenbaugh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Luckenbaugh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Luckenbaugh more than expected).

Fields of papers citing papers by David A. Luckenbaugh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Luckenbaugh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Luckenbaugh. The network helps show where David A. Luckenbaugh may publish in the future.

Co-authors

The 25 scholars most cited alongside David A. Luckenbaugh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David A. Luckenbaugh Line = papers co-authored together David A. Luckenbaugh links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials Journal of Affective Disorders ·Elizabeth D. Ballard, Kathleen E. Wills, Níall Lally, Erica M. Richards, David A. Luckenbaugh, Tessa L. Walls, Rezvan Ameli, Mark J. Niciu, Nancy E. Brutsché, Lawrence Park, Carlos A. Zarate	2017	101
2	The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder Journal of Psychopharmacology ·Mark J. Niciu, Nicolas D. Iadarola, Dipavo Banerjee, David A. Luckenbaugh, Minkyung Park, Marc S. Lener, Lawrence Park, Dawn F. Ionescu, Elizabeth D. Ballard, Nancy E. Brutsché, Nirmala Akula, Francis J. McMahon, Rodrigo Machado‐Vieira, Allison C. Nugent, Carlos A. Zarate	2017	18
3	Recognition of emotional facial expressions in anxious and nonanxious depression Comprehensive Psychiatry ·Hannah Berg, Elizabeth D. Ballard, David A. Luckenbaugh, Allison C. Nugent, Dawn F. Ionescu, Carlos A. Zarate	2016	18
4	The role of adipokines in the rapid antidepressant effects of ketamine Molecular Psychiatry ·Rodrigo Machado‐Vieira, Philip W. Gold, David A. Luckenbaugh, Elizabeth D. Ballard, Erica M. Richards, Ioline D. Henter, RAFAEL TEIXEIRA DE SOUSA, Mark J. Niciu, P Yuan, Carlos A. Zarate	2016	82
5	A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression Psychopharmacology ·Erica M. Richards, Daniel C. Mathews, David A. Luckenbaugh, Dawn F. Ionescu, Rodrigo Machado‐Vieira, Mark J. Niciu, Wallace C. Duncan, Neal M. Nolan, Jose Franco‐Chaves, Thomas J. Hudzik, Carla Maciag, Shuang Li, A.J. Cross, Mark A. Smith, Carlos A. Zarate	2016	59
6	Safety of research into severe and treatment-resistant mood disorders: analysis of outcome data from 12 years of clinical trials at the US National Institute of Mental Health The Lancet Psychiatry ·Allison C. Nugent, Nicolas D. Iadarola, Frank Miller, David A. Luckenbaugh, Carlos A. Zarate	2016	10
7	An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder Journal of Affective Disorders ·Leorey N. Saligan, David A. Luckenbaugh, Elizabeth E. Slonena, Rodrigo Machado‐Vieira, Carlos A. Zarate	2016	36
8	Neural correlates of change in major depressive disorder anhedonia following open-label ketamine Journal of Psychopharmacology ·Níall Lally, Allison C. Nugent, David A. Luckenbaugh, Mark J. Niciu, Jonathan P. Roiser, Carlos A. Zarate	2015	165
9	Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant Journal of Psychiatric Research ·Elizabeth D. Ballard, David A. Luckenbaugh, Erica M. Richards, Tessa L. Walls, Nancy E. Brutsché, Rezvan Ameli, Mark J. Niciu, Jennifer L. Vande Voort, Carlos A. Zarate	2015	56
10	Neural Correlates of Suicidal Ideation and Its Reduction in Depression The International Journal of Neuropsychopharmacology ·Elizabeth D. Ballard, Níall Lally, Allison C. Nugent, Maura L. Furey, David A. Luckenbaugh, Carlos A. Zarate	2014	55
11	Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: A double-blind, randomized pilot study Journal of Affective Disorders ·Jose Franco‐Chaves, Camilo F. Mateus, David A. Luckenbaugh, Pedro E. Martinez, Alan G. Mallinger, Carlos A. Zarate	2013	31
12	Unmedicated, remitted patients with major depression have decreased serum immunoglobulin A Neuroscience Letters ·Philip W. Gold, M. Pavlatou, Paul J. Carlson, David A. Luckenbaugh, Rene Costello, Omer Bonne, György Csákó, Wayne C. Drevets, Alan T. Remaley, Dennis S. Charney, Alexander Neumeister, Mitchel A. Kling	2012	17
13	Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression Biological Psychiatry ·Carlos A. Zarate, Nancy E. Brutsché, Gonzalo Laje, David A. Luckenbaugh, Swarajya Lakshmi Vattem Venkata, Anuradha Ramamoorthy, Ruin Moaddel, Irving W. Wainer	2012	223
14	Early tobacco smoking in adolescents with externalizing disorders: Inferences for reward function Nicotine & Tobacco Research ·Will M. Aklin, Eric T. Moolchan, David A. Luckenbaugh, Monique Ernst	2009	11
15	Neural Response to Catecholamine Depletion in Unmedicated Subjects With Major Depressive Disorder in Remission and Healthy Subjects Archives of General Psychiatry ·Gregor Hasler, Stephen J. Fromm, Paul J. Carlson, David A. Luckenbaugh, Tracy Waldeck, Marilla Geraci, Jonathan P. Roiser, Alexander Neumeister, N Meyers, Dennis S. Charney, Wayne C. Drevets	2008	141
16	A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression American Journal of Psychiatry ·Carlos A. Zarate, Jaskaran Singh, Jorge A. Quiroz, Georgette De Jesus, Kirk K. Denicoff, David A. Luckenbaugh, Husseini K. Manji, Dennis S. Charney	2006	310
17	Reduced Serotonin Type 1_AReceptor Binding in Panic Disorder: Figure 1. Journal of Neuroscience ·Alexander Neumeister, Earle Bain, Allison C. Nugent, Richard E. Carson, Omer Bonne, David A. Luckenbaugh, William C. Eckelman, Peter Herscovitch, Dennis S. Charney, Wayne C. Drevets	2004	272
18	Evidence for continuing neuropsychological impairments in depression Journal of Affective Disorders ·Petra Weiland-Fiedler, Kristine Erickson, Tracy Waldeck, David A. Luckenbaugh, Daniel G. Pike, Omer Bonne, Dennis S. Charney, Alexander Neumeister	2004	255
19	Principal components of the beck depression inventory and regional cerebral metabolism in unipolar and bipolar depression Biological Psychiatry ·Robert T. Dunn, Tim A. Kimbrell, Terence A. Ketter, Mark A. Frye, Mark W Willis, David A. Luckenbaugh, Robert M. Post	2002	150
20	Unique design issues in clinical trials of patients with bipolar affective disorder Journal of Psychiatric Research ·Robert M. Post, David A. Luckenbaugh	2002	21

About David A. Luckenbaugh

David A. Luckenbaugh is a scholar working on Biological Psychiatry, Behavioral Neuroscience, Psychiatry and Mental health, Pharmacology and Experimental and Cognitive Psychology, having authored 159 papers that have together received 17.9k indexed citations. Recurring topics across this work include Treatment of Major Depression (71 papers), Bipolar Disorder and Treatment (61 papers), Tryptophan and brain disorders (47 papers), Functional Brain Connectivity Studies (25 papers), Mental Health Research Topics (21 papers), Stress Responses and Cortisol (20 papers), Electroconvulsive Therapy Studies (14 papers) and Child and Adolescent Psychosocial and Emotional Development (13 papers). The work is most often cited by research in Biological Psychiatry (6.9k citations), Behavioral Neuroscience (2.0k citations), Pharmacology (8.2k citations), Psychiatry and Mental health (6.0k citations) and Cellular and Molecular Neuroscience (4.7k citations). David A. Luckenbaugh has collaborated with scholars based in United States, Czechia and Netherlands. Frequent co-authors include Carlos A. Zarate, Nancy E. Brutsché, Dennis S. Charney, Husseini K. Manji, Rezvan Ameli, Jaskaran Singh, Paul J. Carlson, Robert M. Post, Lobna Ibrahim and Rodrigo Machado‐Vieira. Their work appears in journals such as Biological Psychiatry, The Journal of Clinical Psychiatry, Journal of Affective Disorders, American Journal of Psychiatry and Bipolar Disorders.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact